Valuation Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)
Stocks
RMDA
EGS381B1C015
Pharmaceuticals
|
End-of-day quote
Egyptian Exchange
2026-11-05
|
5-day change | 1st Jan Change | ||
| 5.500 EGP | +0.36% |
|
+5.77% | +65.17% |
Company Valuation: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,400 | 2,892 | 2,459 | 5,022 | 6,660 | 11,180 | - | - |
| Change | - | 20.51% | -14.96% | 104.18% | 32.63% | 67.88% | - | - |
| Enterprise Value (EV) 1 | 2,761 | 2,892 | 3,223 | 6,290 | 8,967 | 13,282 | 12,903 | 12,525 |
| Change | - | 4.76% | 11.43% | 95.16% | 42.57% | 48.12% | -2.86% | -2.93% |
| P/E | 14.4x | 12.9x | 11.1x | 14.4x | 24.9x | 20x | 14x | 10.6x |
| PBR | 1.78x | - | 1.4x | 2.5x | 3.07x | 4.24x | 3.54x | 2.94x |
| PEG | - | 0.3x | -5.84x | 0.3x | -1x | 0x | 0.3x | 0.3x |
| Capitalization / Revenue | 1.93x | 1.95x | 1.28x | 1.83x | 1.63x | 2.31x | 1.98x | 1.72x |
| EV / Revenue | 2.21x | 1.95x | 1.68x | 2.29x | 2.19x | 2.74x | 2.28x | 1.93x |
| EV / EBITDA | 8.63x | 6.83x | 6.05x | 8.19x | 7.64x | 9.31x | 7.45x | 6.14x |
| EV / EBIT | 10.1x | 8.09x | 7.32x | 8.83x | 8.3x | 10.1x | 8.08x | 6.63x |
| EV / FCF | - | - | -10.8x | - | -44.9x | -615x | 35.3x | 26.7x |
| FCF Yield | - | - | -9.25% | - | -2.23% | -0.16% | 2.84% | 3.75% |
| Dividend per Share 2 | - | - | - | - | - | 0.0777 | 0.1506 | 0.2138 |
| Rate of return | - | - | - | - | - | 1.41% | 2.74% | 3.89% |
| EPS 2 | 0.0826 | 0.1147 | 0.1125 | 0.1756 | 0.1336 | 0.2753 | 0.3935 | 0.517 |
| Distribution rate | - | - | - | - | - | 28.2% | 38.3% | 41.4% |
| Net sales 1 | 1,246 | 1,484 | 1,922 | 2,743 | 4,096 | 4,843 | 5,661 | 6,485 |
| EBITDA 1 | 319.8 | 423.2 | 532.9 | 767.8 | 1,173 | 1,427 | 1,733 | 2,041 |
| EBIT 1 | 273.6 | 357.7 | 440.1 | 712.5 | 1,081 | 1,311 | 1,597 | 1,890 |
| Net income 1 | 181.1 | 245.7 | 244.9 | 373.2 | 298.5 | 567.7 | 798.8 | 1,040 |
| Net Debt 1 | 360.6 | - | 763.5 | 1,268 | 2,307 | 2,102 | 1,722 | 1,344 |
| Reference price 2 | 1.191 | 1.474 | 1.247 | 2.523 | 3.330 | 5.500 | 5.500 | 5.500 |
| Nbr of stocks (in thousands) | 2,015,271 | 1,962,431 | 1,972,910 | 1,990,031 | 2,000,000 | 2,032,817 | - | - |
| Announcement Date | 2/24/22 | 3/7/23 | 3/19/24 | 3/10/25 | 3/31/26 | - | - | - |
1EGP in Million2EGP
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.98x | 2.74x | 9.31x | 1.41% | 208M | |
| 39.62x | 13.42x | 28.51x | 0.5% | 1,206B | |
| 40.43x | 6.79x | 19.09x | 1.93% | 665B | |
| 37.52x | 8.51x | 17.57x | 2.38% | 515B | |
| 20.98x | 5.12x | 12.74x | 2.57% | 381B | |
| 97.18x | 5.94x | 25.33x | 2.32% | 362B | |
| 23.18x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.46x | 4.89x | 13.77x | 1.79% | 289B | |
| 23.75x | 7.3x | 13.55x | 2.19% | 249B | |
| -39.18x | 7.28x | 45.82x | 1.98% | 207B | |
| Average | 28.79x | 6.79x | 20.00x | 1.98% | 418B | |
| Weighted average by Cap. | 35.67x | 8.55x | 21.86x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RMDA Stock
- Valuation Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)
Select your edition
All financial news and data tailored to specific country editions
